Table 1 Clinical studies of triptan + NSAID combinations in the treatment of migraine (published 1999-2009)

Krymchantowski et al. 1999 [24]

retrospective clinical case series

sumatriptan (100 mg)

+ tolfenamic acid 200 mg

single dose/attack (number of treated attacks per patient not reported)

Krymchantowski 2000 [25]

open-label study

sumatriptan (100 mg)

+ naproxen sodium (550 mg)

single dose

(3 attacks treated)

Smith et al. 2005 [26]

multicenter, randomized, double-blind, double-dummy, placebo-controlled, four-arm study

sumatriptan (50 mg)

+ naproxen sodium (500 mg)

sumatriptan (50 mg)

naproxen sodium (500 mg)

placebo

single dose

Brandes et al. 2007 [27]

two replicate, randomized, double-blind, single attack, parallel-group studies

sumatriptan (85 mg)

+ naproxen sodium (500 mg)

sumatriptan (85 mg)

naproxen sodium (500 mg)

placebo

single dose

Lipton et al. 2009 [28]

two identical randomized, placebo-controlled, crossover studies

sumatriptan (85 mg)

+ naproxen sodium (500 mg)

placebo

single dose

(4 attacks treated)

report of 2 clinical studies

Krymchantowski & Barbosa 2002 [29]

open label pilot study

rizatriptan (10 mg)

+ rofecoxib (25 mg)

rizatriptan (10 mg)

single dose

(3 attacks treated)

Krymchantowski & Bigal 2004 [30]

randomized, open-label, cross-over study

rizatriptan (10 mg)

+ tolfenamic acid (200 mg)

rizatriptan (10 mg)

+ rofecoxib (50 mg)

rizatriptan (10 mg)

single dose

(2 attacks treated)

Krymchantowski et al. 2006 [31]

double-blind, randomized, cross-over study

rizatriptan (10 mg)

+ trimebutine (200 mg)

rizatriptan (10 mg)

single dose

(2 attacks treated)

Freitag et al. 2008 [32]

randomized, double-blind, placebo-controlled study

rizatriptan (10 mg)

+ acetaminophen (1000 mg)

rizatriptan (10 mg)

acetaminophen (1000 mg)

placebo

single dose

Schoenen et al. 2008 [33]

multicenter, double-blind, double-dummy, cross-over pilot study

almotriptan (12.5 mg)

+ aceclofenac (100 mg)

almotriptan (12.5 mg)

+ placebo

single dose